Penetrium Bioscience

At a glance

Penetrium Bioscience filed 71 disclosures in the last 12 months, including 11 5% holder, 8 insider, 2 issuance and 1 m&a. The most recent key filing was on Oct 19: Auditor bought 10,000 sh on the market, Oct 15.

Revenue for 2025 was ₩9.3B, down 4.8% on 2024. It made an operating loss of ₩7.4B. Debt was 52% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.8B and operating loss of ₩3.7B.

The 2025 annual report lists 110 employees with an average tenure of 3.3 years and average pay of ₩72.6M, #527 of 1,829 listed companies by average pay. Its 10 directors and auditors were paid ₩63.5M each on average. It paid no cash dividend for 2025. 현대바이오사이언스(주) and related parties held 36.92% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 37.57% on Oct 14.

From the 2025 annual report

Staff: 110 (29 men, 81 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩7.3B. Directors and auditors: 10, paid ₩635.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

현대바이오사이언스(주) holds 25.95%; with 2 related parties the group holds 36.92% of common shares at year end (from 35.47% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports